497 related articles for article (PubMed ID: 22093488)
1. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
[TBL] [Abstract][Full Text] [Related]
2. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
Oliva EM; Harris AH; Trafton JA; Gordon AJ
Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887
[TBL] [Abstract][Full Text] [Related]
3. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
[TBL] [Abstract][Full Text] [Related]
4. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
Turner BJ; Laine C; Lin YT; Lynch K
Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
[TBL] [Abstract][Full Text] [Related]
5. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
[TBL] [Abstract][Full Text] [Related]
6. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
[TBL] [Abstract][Full Text] [Related]
7. Comparison of costs and utilization among buprenorphine and methadone patients.
Barnett PG
Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
9. Exposure to opioid maintenance treatment reduces long-term mortality.
Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
[TBL] [Abstract][Full Text] [Related]
10. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
[TBL] [Abstract][Full Text] [Related]
11. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.
Clark RE; Samnaliev M; Baxter JD; Leung GY
Health Aff (Millwood); 2011 Aug; 30(8):1425-33. PubMed ID: 21821560
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with Medicaid patients' access to buprenorphine treatment.
Baxter JD; Clark RE; Samnaliev M; Leung GY; Hashemi L
J Subst Abuse Treat; 2011 Jul; 41(1):88-96. PubMed ID: 21459544
[TBL] [Abstract][Full Text] [Related]
13. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
Fingerhood MI; King VL; Brooner RK; Rastegar DA
Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
[TBL] [Abstract][Full Text] [Related]
14. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
15. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
Bell J; Trinh L; Butler B; Randall D; Rubin G
Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
[TBL] [Abstract][Full Text] [Related]
17. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration.
Gordon AJ; Kavanagh G; Krumm M; Ramgopal R; Paidisetty S; Aghevli M; Goodman F; Trafton J; Liberto J
Psychol Addict Behav; 2011 Jun; 25(2):215-24. PubMed ID: 21480679
[TBL] [Abstract][Full Text] [Related]
18. Opioid dependence: rationale for and efficacy of existing and new treatments.
Fiellin DA; Friedland GH; Gourevitch MN
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
[TBL] [Abstract][Full Text] [Related]
19. [Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report].
Radomska M; Pach J; Chrostek Maj J
Przegl Lek; 2001; 58(4):351-3. PubMed ID: 11450367
[TBL] [Abstract][Full Text] [Related]
20. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
